MA53429A - Sels d'addition d'acide succinate et fumarate de dérivés de pipérazine utiles en tant qu'inhibiteurs de glycosidase - Google Patents
Sels d'addition d'acide succinate et fumarate de dérivés de pipérazine utiles en tant qu'inhibiteurs de glycosidaseInfo
- Publication number
- MA53429A MA53429A MA053429A MA53429A MA53429A MA 53429 A MA53429 A MA 53429A MA 053429 A MA053429 A MA 053429A MA 53429 A MA53429 A MA 53429A MA 53429 A MA53429 A MA 53429A
- Authority
- MA
- Morocco
- Prior art keywords
- succinate
- derivatives useful
- piperazine derivatives
- additional salts
- glycosidase inhibitors
- Prior art date
Links
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical class C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 title 1
- 239000003316 glycosidase inhibitor Substances 0.000 title 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 title 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 title 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18190155 | 2018-08-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53429A true MA53429A (fr) | 2022-03-30 |
Family
ID=63363926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053429A MA53429A (fr) | 2018-08-22 | 2019-08-22 | Sels d'addition d'acide succinate et fumarate de dérivés de pipérazine utiles en tant qu'inhibiteurs de glycosidase |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20210198250A1 (fr) |
| EP (1) | EP3841093B1 (fr) |
| JP (1) | JP7407171B2 (fr) |
| KR (1) | KR20210049849A (fr) |
| CN (1) | CN113166083A (fr) |
| AU (1) | AU2019324522A1 (fr) |
| BR (1) | BR112021003022A2 (fr) |
| CA (1) | CA3110032A1 (fr) |
| EA (1) | EA202190275A1 (fr) |
| ES (1) | ES2954474T3 (fr) |
| HU (1) | HUE063226T2 (fr) |
| IL (1) | IL280841B1 (fr) |
| MA (1) | MA53429A (fr) |
| MX (1) | MX2021002111A (fr) |
| PL (1) | PL3841093T3 (fr) |
| SG (1) | SG11202101651RA (fr) |
| WO (1) | WO2020039030A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180132060A (ko) | 2016-02-25 | 2018-12-11 | 아셰뉴론 에스아 | 피페라진 유도체의 산 부가 염 |
| US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
| EP3419971B1 (fr) | 2016-02-25 | 2022-04-20 | Asceneuron SA | Inhibiteurs de glycosidases |
| EP3672959A1 (fr) | 2017-08-24 | 2020-07-01 | Asceneuron SA | Inhibiteurs linéaires de la glycosidase |
| WO2020039028A1 (fr) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Inhibiteurs de tétrahydro-benzoazépine glycosidase |
| WO2020039029A1 (fr) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Composés spiro utilisés en tant qu'inhibiteurs de glycosidases |
| US12016852B2 (en) | 2018-08-22 | 2024-06-25 | Asceneuron Sa | Pyrrolidine glycosidase inhibitors |
| CN117471001B (zh) * | 2023-12-26 | 2024-03-26 | 山东百诺医药股份有限公司 | 一种瑞卢戈利起始物料中n-溴代琥珀酰亚胺含量的测定方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6563017B2 (ja) * | 2014-08-28 | 2019-08-21 | エースニューロン・ソシエテ・アノニム | グリコシダーゼ阻害剤 |
| WO2018153508A2 (fr) * | 2017-02-24 | 2018-08-30 | Asceneuron S.A. | Inhibiteurs de la sulfoximine glycosidase |
| KR20180132060A (ko) * | 2016-02-25 | 2018-12-11 | 아셰뉴론 에스아 | 피페라진 유도체의 산 부가 염 |
| US11261183B2 (en) * | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
| MX2018010191A (es) * | 2016-02-25 | 2019-05-20 | Asceneuron S A | Inhibidores de glucosidasa. |
| EP3419971B1 (fr) * | 2016-02-25 | 2022-04-20 | Asceneuron SA | Inhibiteurs de glycosidases |
-
2019
- 2019-08-22 HU HUE19759533A patent/HUE063226T2/hu unknown
- 2019-08-22 EP EP19759533.3A patent/EP3841093B1/fr active Active
- 2019-08-22 PL PL19759533.3T patent/PL3841093T3/pl unknown
- 2019-08-22 IL IL280841A patent/IL280841B1/en unknown
- 2019-08-22 MA MA053429A patent/MA53429A/fr unknown
- 2019-08-22 ES ES19759533T patent/ES2954474T3/es active Active
- 2019-08-22 JP JP2021509145A patent/JP7407171B2/ja active Active
- 2019-08-22 BR BR112021003022-0A patent/BR112021003022A2/pt unknown
- 2019-08-22 MX MX2021002111A patent/MX2021002111A/es unknown
- 2019-08-22 WO PCT/EP2019/072474 patent/WO2020039030A1/fr unknown
- 2019-08-22 CN CN201980055121.7A patent/CN113166083A/zh active Pending
- 2019-08-22 KR KR1020217008344A patent/KR20210049849A/ko not_active Application Discontinuation
- 2019-08-22 US US17/269,811 patent/US20210198250A1/en active Pending
- 2019-08-22 EA EA202190275A patent/EA202190275A1/ru unknown
- 2019-08-22 CA CA3110032A patent/CA3110032A1/fr active Pending
- 2019-08-22 SG SG11202101651RA patent/SG11202101651RA/en unknown
- 2019-08-22 AU AU2019324522A patent/AU2019324522A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HUE063226T2 (hu) | 2024-01-28 |
| IL280841B1 (en) | 2024-08-01 |
| ES2954474T3 (es) | 2023-11-22 |
| JP2021535103A (ja) | 2021-12-16 |
| US20210198250A1 (en) | 2021-07-01 |
| CA3110032A1 (fr) | 2020-02-27 |
| BR112021003022A2 (pt) | 2021-05-11 |
| WO2020039030A1 (fr) | 2020-02-27 |
| IL280841A (en) | 2021-04-29 |
| SG11202101651RA (en) | 2021-03-30 |
| EP3841093B1 (fr) | 2023-06-21 |
| CN113166083A (zh) | 2021-07-23 |
| PL3841093T3 (pl) | 2023-12-11 |
| EP3841093C0 (fr) | 2023-06-21 |
| AU2019324522A1 (en) | 2021-03-04 |
| EP3841093A1 (fr) | 2021-06-30 |
| EA202190275A1 (ru) | 2021-08-02 |
| MX2021002111A (es) | 2021-07-16 |
| KR20210049849A (ko) | 2021-05-06 |
| JP7407171B2 (ja) | 2023-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53429A (fr) | Sels d'addition d'acide succinate et fumarate de dérivés de pipérazine utiles en tant qu'inhibiteurs de glycosidase | |
| MA50655A (fr) | Sels de dérivés de pyrrolotriazine utiles en tant qu'inhibiteurs de tam | |
| CO2019013021A2 (es) | Amidas de piridona deuteradas y sus profármacos como moduladores de los canales de sodio | |
| CY1124404T1 (el) | Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5 και μεθοδοι χρησης αυτων | |
| MA51610A (fr) | Dérivés d'imidazole fusionnés utilisés en tant qu'inhibiteurs d'il-17 | |
| MA46339A (fr) | Dérivés de cyanopyrrolidine ayant une activité en tant qu'inhibiteurs de l'usp 30 | |
| BR112013001015A2 (pt) | método por tratar doenças oftálmicas que usam compostos de inibidor de cinase em formas de prodrug | |
| SV2019005823A (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
| EA201891438A1 (ru) | Кислотно-аддитивные соли производных пиперазина | |
| CY1117122T1 (el) | Παραγωγα πυραζολοσπειροκετονης για χρηση ως αναστολεις ακετyλ-coa καρβοξυλασης | |
| BR112018008397A2 (pt) | derivados de di-hidroimidazopirazinona úteis no tratamento do câncer | |
| CY1117080T1 (el) | Θεραπευτικος παραγοντας για στενωση του σπονδυλικου σωληνα | |
| AR057874A1 (es) | Aminopirimidinas utiles como inhibidores de quinasa | |
| UY32379A (es) | Derivados de n-heteroarilo sulfonammida sustituidos, sales, solvatos o tautómero farmacéuticamente aceptables, procesos de preparación, intermedios, composicones conteniéndolos y aplicaciones. | |
| CL2021001396A1 (es) | Derivados de panteteína y usos de los mismos | |
| AR058180A1 (es) | Indeno derivados, su preparacion y su uso como medicamentos | |
| BR112018069712A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a. | |
| CL2018001570A1 (es) | Derivados de compuestos de 3,5-difenil-diazol solubles en agua | |
| MA53164A (fr) | Dérivés de tyrosine amide utilisés en tant qu'inhibiteurs de la rho-kinase | |
| BR112016013618A8 (pt) | derivados de maleimida como moduladores de série de reação de wnt, seus usos, composição farmacêutica e processo para a preparação dos mesmos | |
| CL2022001357A1 (es) | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso | |
| MA51283A (fr) | Dérivés de tyrosine en tant qu'inhibiteurs de kinase rho | |
| DK3976581T3 (da) | Tartaric acid salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine | |
| BR112015019307A2 (pt) | derivados de ácido butanoico substituído com bisfenila como inibidores de nep com eficácia in vivo melhorada | |
| ES2982095T3 (es) | Sales de adición de ácidos orgánicos de S-pindolol |